Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Posted on by Pencis

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012

sungil im | Arrhythmia | Best Researcher Award

Posted on by Pencis

Dr. sungil im | Arrhythmia | Best Researcher Award

Dr. sungil im, kosin university, South Korea

Dr. Sungil Im is an Associate Professor of Cardiology at Kosin University Gospel Hospital, South Korea. With a distinguished career spanning over two decades, he specializes in cardiac electrophysiology, atrial myopathy, and advanced ablation techniques for arrhythmias. Dr. Im’s global expertise includes serving as an international cooperation doctor under KOICA in Kazakhstan and contributing to leading institutions like Korea University Medical Center and Samsung Medical Center. A Fellow of the American College of Cardiology (FACC) and European Society of Cardiology (FESC), his impactful research and clinical trials continue to shape advancements in cardiology worldwide.

Author Profile

Orcid Profile

Google Scholar Profile

📚 EARLY ACADEMIC PURSUITS:

Dr. Sungil Im’s journey in medicine began with a strong foundation in internal medicine and cardiology. After obtaining his Korean Medical Doctor license in 2003, he pursued a rigorous residency at Gyeong Sang National University Hospital, specializing in general internal medicine and cardiology. His academic milestones were marked by a continuous quest for excellence, which paved the way for his clinical expertise in cardiac electrophysiology.

🩺 PROFESSIONAL ENDEAVORS:

Dr. Im’s professional journey is a testament to his dedication and versatility. From 2008 to 2011, he served as an international cooperation doctor under KOICA at the Korea-Kazakhstan Friendship Hospital. This experience underscored his global commitment to advancing healthcare. Upon returning to Korea, he held key positions such as Clinical Fellow and Assistant Professor at esteemed institutions, including the Korea University Medical Center and Samsung Medical Center. Currently, he is an Associate Professor at Kosin University Gospel Hospital, where he continues to contribute significantly to cardiology education and clinical practice.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ARRHYTHMIA:

Dr. Im’s research interests are deeply rooted in advanced cardiac electrophysiology. His groundbreaking studies focus on atrial myopathy, cryoablation techniques for atrial fibrillation, and ventricular tachycardia ablation. His investigations into arrhythmogenesis and inflammation in atrial fibrillation patients have opened new avenues for understanding cardiac diseases. Additionally, his work on the association between ventricular arrhythmias and stroke has provided critical insights into improving patient outcomes.

🌍 IMPACT AND INFLUENCE:

Dr. Im’s influence extends beyond academia and clinical practice. He is a Fellow of the American College of Cardiology (FACC) and the European Society of Cardiology (FESC), reflecting his global recognition. As a board member of various Korean cardiology societies, he plays a vital role in shaping policies and advancing the field. His participation in multicenter clinical trials has further reinforced his reputation as a pioneer in cardiology research.

📖 ACADEMIC CITES:

Dr. Im has authored and contributed to numerous peer-reviewed studies and clinical trials, particularly in the fields of hypertension, medication adherence, and electrophysiology. His scholarly work is widely cited and respected, showcasing his intellectual contributions to cardiology.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sungil Im’s legacy is one of relentless pursuit of excellence and innovation. His dedication to advancing cardiac care, mentoring future cardiologists, and driving groundbreaking research continues to leave a lasting impact. Looking ahead, his work promises to further enhance our understanding of complex cardiac disorders and improve global healthcare standards.

🌟 CONCLUSION:

Dr. Sungil Im exemplifies the qualities of a world-class researcher and educator. With a career marked by global service, pioneering research, and academic leadership, he stands as a beacon of inspiration in the field of cardiology. His legacy will undoubtedly influence generations to come.

TOP NOTABLE PUBLICATIONS

Pulsed field ablation of left ventricular myocardium in a swine infarct model

Authors: SI Im, S Higuchi, A Lee, C Stillson, E Buck, B Morrow, K Schneider, …

Journal: Clinical Electrophysiology

Year: 2022

Predictors of adverse outcome in patients with frequent premature ventricular complexes: the ABC-VT risk score

Authors: A Voskoboinik, A Hadjis, C Alhede, SI Im, H Park, J Moss, GM Marcus, …

Journal: Heart Rhythm

Year: 2020

Identification of markers associated with development of stroke in “Clinically Low‐Risk” atrial fibrillation patients

Authors: SY Shin, SJ Han, JS Kim, SI Im, J Shim, J Ahn, EM Lee, YM Park, JH Kim, …

Journal: Journal of the American Heart Association

Year: 2019

Effect of epicardial pulsed field ablation directly on coronary arteries

Authors: S Higuchi, SI Im, C Stillson, ED Buck, S Jerrell, CW Schneider, M Speltz, …

Journal: Clinical Electrophysiology

Year: 2022

Gap junction remodeling by chronic pressure overload is related to the increased susceptibility to atrial fibrillation in rat heart

Authors: SY Shin, WM Jo, TJ Min, BK Kim, DH Song, SH Hyeon, JE Kwon, WS Lee, …

Journal: EP Europace

Year: 2015

Usefulness of neutrophil/lymphocyte ratio in predicting early recurrence after radiofrequency catheter ablation in patients with atrial fibrillation

Authors: SI Im, SY Shin, JO Na, YH Kim, CU Choi, SH Kim, JW Kim, EJ Kim, …

Journal: International Journal of Cardiology

Year: 2013

Impact of low-dose aspirin on coronary artery spasm as assessed by intracoronary acetylcholine provocation test in Korean patients

Authors: JY Park, SW Rha, KL Poddar, S Ramasamy, KY Chen, YJ Li, BG Choi, …

Journal: Journal of Cardiology

Year: 2012

Thyrotoxicosis with coronary spasm that required coronary artery bypass surgery

Authors: SM Lee, TS Jung, JR Hahm, SI Im, SK Kim, KJ Lee, JM Lee, SI Chung

Journal: Internal Medicine

Year: 2007

Risk factor algorithm used to predict frequent premature ventricular contraction-induced cardiomyopathy

Authors: KM Park, SI Im, SJ Park, JS Kim, YK On

Journal: International Journal of Cardiology

Year: 2017

Impact of periodontitis as representative of chronic inflammation on long-term clinical outcomes in patients with atrial fibrillation

Authors: SI Im, J Heo, BJ Kim, KI Cho, HS Kim, JH Heo, JY Hwang

Journal: Open Heart

Year: 2018

Yu Tian | Cardiac immunology | Best Researcher Award

Posted on by Pencis
Dr. Yu Tian, Jiangsu University, China

Dr. Yu Tian is a prominent researcher at Jiangsu University, China, specializing in immunology and molecular biology. With a focus on immune cell migration, viral myocarditis, and neuroinflammation, Dr. Tian has contributed significantly to understanding immune responses in cardiovascular and neurological diseases. He has published numerous articles in prestigious journals such as Journal of Leukocyte Biology and International Immunopharmacology, and his research explores therapeutic targets like HMGB1 and IL-22. Dr. Tian’s work plays a critical role in advancing treatment strategies for diseases involving immune system dysfunction and inflammation.

Profile:
Education:

 

Dr. Yu Tian completed his Bachelor’s Degree in Medicine at Qinghai University from September 2011 to June 2016. He then pursued his Master’s and Ph.D. at Jiangsu University, School of Medicine, from September 2016 to September 2022, where he specialized in immunology and molecular biology. His academic journey has laid a strong foundation for his research in immune cell function and disease mechanisms, contributing to his current role as a researcher at Jiangsu University.

Professional Experience:

 

Dr. Yu Tian is currently a researcher at Jiangsu University, School of Life Sciences, specifically within the International Genomics Research Center, a position he has held since December 2022. In this role, he leads a horizontal research project investigating the effects of HMGB1 on immune cells, which commenced in 2023. Additionally, Dr. Tian is actively involved in a National Natural Science Foundation of China (NSFC)-funded project that examines the role of IGF-1 in heart damage following myocardial infarction, scheduled for 2025 to 2027. His work contributes significantly to advancing the understanding of immune mechanisms in cardiovascular health.

 

Research Interest:

 

Dr. Yu Tian’s research interests lie in immunology, specifically investigating the role of HMGB1 in immune cell responses. He focuses on cardiovascular diseases, exploring the mechanisms that contribute to heart damage and myocardial infarction. Additionally, Dr. Tian studies adipose tissue accumulation and its impact on worsening heart conditions, aiming to uncover potential therapeutic targets for improving cardiovascular health. His work seeks to enhance the understanding of immune and metabolic interactions in the context of heart disease.

Conclusion:

Dr. Yu Tian is an accomplished researcher at Jiangsu University, specializing in immunology and cardiovascular diseases. With a solid educational background and a focus on the role of HMGB1 in immune responses, he is dedicated to unraveling the complex mechanisms underlying heart damage and myocardial infarction. His ongoing research projects aim to deepen the understanding of immune cell interactions and metabolic factors that exacerbate cardiovascular conditions. Through his contributions, Dr. Tian is poised to make a significant impact on the field, advancing potential therapeutic strategies for improving heart health and addressing related diseases.

Top Notable Publications:

Yin, P., Su, Z., Shu, X., Dong, Z., Tian, Y. (2024). Role of TREM2 in immune and neurological diseases: Structure, function, and implications. International Immunopharmacology, 143, 113286. 0 citations

Tian, Y., Gong, X., Qin, D., Liu, F., Su, Z. (2023). S1PR1-dependent migration of ILC3s from intestinal tissue to the heart in a mouse model of viral myocarditis. Journal of Leukocyte Biology, 114(2), 154–163. 7 citations

Tian, Y., Chen, R., Su, Z. (2023). HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease. Cellular and Molecular Neurobiology, 43(1), 47–58. 6 citations

Chen, R., Liu, F., Xia, L., Xu, H., Su, Z. (2022). B10 cells decrease fibrosis progression following cardiac injury partially by IL-10 production and regulating hyaluronan secretion. Journal of Leukocyte Biology, 111(2), 415–425. 1 citation

Cao, Y., Tian, Y., Liu, Y., Su, Z. (2022). Reg3β: A Potential Therapeutic Target for Tissue Injury and Inflammation-Associated Disorders. International Reviews of Immunology, 41(2), 160–170. 2 citations

Che, Y., Tian, Y., Chen, R., Liu, F., Su, Z. (2021). IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Biochimica et Biophysica Acta – Molecular Basis of Disease, 1867(9), 166171. 26 citations

Chen, W., Yao, S., Wan, J., Yao, Y., Zhang, X. (2021). BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment. Journal of Controlled Release, 333, 129–138. 45 citations

Li, J., Xia, L., Liu, F., Chen, R., Su, Z. (2021). lncRNA187415.1 silence in BCAMs ameliorated breast cancer progression by blocking C/EBPβ-lncRNA187415.1-CISH axis and reversing pro-tumor characteristic of BCAMs. Clinical and Translational Medicine, 11(5), e407. 1 citation

Huang, L., Wan, J., Wu, Y., Su, Z., Xu, H. (2021). Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sciences, 270, 119142. 26 citations

Wan, J., Wu, Y., Huang, L., Wang, S., Xu, H. (2021). ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+ T cells. Cancer Letters, 502, 34–43. 31 citations